Monoclonal Antibodies

PUR001 for Solid Tumors

The University of Texas MD Anderson Cancer Center, Houston, TX
PUR001Phase 1RecruitingResearch Sponsored by Purinomia Biotech, Inc.

Study Summary

This trial is testing a new cancer drug to see if it is safe and effective. The drug will be given to a small group of people to see what effects, if any, it has.

Eligible Conditions
  • Advanced Solid Tumors

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
You have been diagnosed with advanced or metastatic solid tumors and have already tried at least one type of chemotherapy that did not work.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1-1.5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1-1.5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD), if reached
Secondary outcome measures
Area under the concentration time curve (AUC 0-last)
Disease Control Rate (DCR)
Duration of Response (DOR)
+9 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Monotherapy classic "3+3" design dose escalation and expansionExperimental Treatment1 Intervention

Find a site

Who is running the clinical trial?

Purinomia Biotech, Inc.Lead Sponsor
Clinical DevelopmentStudy Director
Purinomia Biotech, Inc.
33 Previous Clinical Trials
87,606 Total Patients Enrolled

Media Library

PUR001 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05234853 — Phase 1
Solid Tumors Research Study Groups: Monotherapy classic "3+3" design dose escalation and expansion
Solid Tumors Clinical Trial 2023: PUR001 Highlights & Side Effects. Trial Name: NCT05234853 — Phase 1
PUR001 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05234853 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the study continue to accept participants?

"As indicated on, this research project is no longer recruiting participants. Initially posted in March 9th 2022 and last updated a few days before that, its closure has opened the doors for 2502 other experiments actively searching for candidates at present."

Answered by AI

What assessments have been made to ensure the safety of PUR001 for individuals undergoing treatment?

"PUR001 has only been assessed in a Phase 1 trial, therefore Power's team assigned it with the lowest safety score of 1. This is due to its lack of data regarding efficacy and safety."

Answered by AI
~2 spots leftby Dec 2023